Pfizer (PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.45 -1.25%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.4%
Join SI Premium – FREE
Pfizer (NYSE: PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants accelerated approval to AstraZeneca's camizestrant combo
- Novartis pelacarsen trial fails to meet primary endpoint
- Micropolis Robotics displays autonomous robots at Dubai investment event
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
